Paraskevas Kosmas I, AbuRahma Ali F, Abularrage Christopher J, Clair Daniel G, Eldrup-Jorgensen Jens, Kashyap Vikram S, Dardik Alan, de Borst Gert J, Dermody Meghan, Faggioli Gianluca, Hicks Caitlin W, Kwolek Christopher J, Lyden Sean P, Mansilha Armando, Van Herzeele Isabelle, Myrcha Piotr, Leal Lorenzo Jose Ignacio, Jim Jeffrey, Pini Rodolfo, Secemsky Eric A, Spinelli Francesco, Capoccia Laura, Stone David H, Stoner Michael C, Zeebregts Clark J, Lal Brajesh K, Schneider Peter A, Malas Mahmoud B, Schermerhorn Marc L
Department of Vascular Surgery, Red Cross Hospital, Athens, Greece.
Department of Surgery, Charleston Area Medical Center/West Virginia University, Charleston, WV.
Ann Vasc Surg. 2025 Jan;110(Pt B):42-53. doi: 10.1016/j.avsg.2024.09.048. Epub 2024 Oct 15.
Transcarotid artery revascularization (TCAR) has emerged as an alternative therapeutic modality to carotid endarterectomy (CEA) and transfemoral carotid artery stenting (TFCAS) for the management of patients with carotid artery stenosis. However, certain issues regarding the indications and contraindications of TCAR remain unanswered or unresolved. The aim of this international, expert-based Delphi consensus document was to attempt to provide some guidance on these topics.
A 3-round Delphi consensus process was performed, including 29 experts. The aim of round 1 was to investigate the differing views and opinions of the participants. Round 2 was carried out after the results from the literature on each topic were provided to the participants. During round 3, the participants had the opportunity to finalize their vote.
Most participants agreed that TCAR can or can probably or possibly be performed within 14 days of a cerebrovascular event, but it is best to avoid it in the first 48 hr. It was felt that TCAR cannot or should not replace TFCAS or CEA, as each procedure has specific indications and contraindications. Symptomatic patients >80 years should probably be treated with TCAR rather than with TFCAS. TCAR can or can probably be used for the treatment of restenosis following CEA or TFCAS. Finally, there is a need for a randomized controlled trial (RCT) to provide better evidence for the unresolved issues.
This Delphi consensus document attempted to assist the decision-making of physicians or interventionalists or vascular surgeons involved in the management of carotid stenosis patients. Furthermore, areas requiring additional research were identified. Future studies and RCTs should provide more evidence to address the unanswered questions regarding TCAR.
经颈动脉血管重建术(TCAR)已成为一种替代颈动脉内膜切除术(CEA)和经股动脉颈动脉支架置入术(TFCAS)的治疗方式,用于治疗颈动脉狭窄患者。然而,关于TCAR的适应证和禁忌证的某些问题仍未得到解答或解决。本基于专家的国际德尔菲共识文件旨在就这些主题提供一些指导。
进行了三轮德尔菲共识过程,包括29名专家。第一轮的目的是调查参与者的不同观点和意见。在向参与者提供每个主题的文献结果后进行第二轮。在第三轮中,参与者有机会确定他们的投票。
大多数参与者同意,TCAR可以或可能或有可能在脑血管事件发生后的14天内进行,但最好在最初的48小时内避免。人们认为,TCAR不能或不应该取代TFCAS或CEA,因为每种手术都有特定的适应证和禁忌证。年龄>80岁的有症状患者可能应接受TCAR而非TFCAS治疗。TCAR可以或可能用于治疗CEA或TFCAS后的再狭窄。最后,需要进行一项随机对照试验(RCT),为未解决的问题提供更好的证据。
本德尔菲共识文件试图协助参与颈动脉狭窄患者管理的内科医生、介入专家或血管外科医生进行决策。此外,确定了需要进一步研究的领域。未来的研究和RCT应提供更多证据,以解决有关TCAR的未回答问题。